Austin M. Dulak, Ph.D.
Affiliations: | 2010 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Molecular BiologyGoogle:
"Austin Dulak"Parents
Sign in to add mentor| Jill M. Siegfried | grad student | 2010 | University of Pittsburgh | |
| (Analyzing the Impact of EGFR-induced c-Met Phosphorylation in Non-Small Cell Lung Cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wong GS, Zhou J, Liu JB, et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine |
| Chen H(, Hattersley M, Rhyasen G, et al. (2016) Abstract 4705: Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in hematological cancers Cancer Research. 76: 4705-4705 |
| Beauchamp EM, Woods BA, Dulak AM, et al. (2014) Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Molecular Cancer Therapeutics. 13: 475-82 |
| Dulak AM, Stojanov P, Peng S, et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genetics. 45: 478-86 |
| Dulak AM, Schumacher SE, van Lieshout J, et al. (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Research. 72: 4383-93 |
| Bandla S, Ruff D, Bass A, et al. (2012) Abstract LB-410: Targeted resequencing of genes frequently mutated in esophageal adenocarcinoma using highly multiplexed Ion Torrent AmpliSeqTM technology and semiconductor sequencing Cancer Research. 72 |
| Dulak AM, Gubish CT, Stabile LP, et al. (2011) HGF-independent potentiation of EGFR action by c-Met. Oncogene. 30: 3625-35 |
| Dulak AM, Gubish CT, Siegfried JM. (2010) Abstract 4123: Induction of motility, invasion, and proliferation by wild-type EGFR depends on c-Met in NSCLC Cancer Research. 70: 4123-4123 |
| Stabile LP, Rothstein ME, Keohavong P, et al. (2008) Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Molecular Cancer Therapeutics. 7: 1913-22 |